Opus Genetics, Inc. (IRD) vs ARS Pharmaceuticals, Inc. (SPRY)
Opus Genetics, Inc. and ARS Pharmaceuticals, Inc. are both Biotechnology companies. Opus Genetics, Inc. and ARS Pharmaceuticals, Inc. are of similar size ($412.7M and $405.2M). ARS Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 4.08% against −36.1%. ARS Pharmaceuticals, Inc. has the higher net margin (−184.3% vs −1,091.8%) and the lower return on invested capital (−335.7% vs 0.00%). Across the 16 metrics below, ARS Pharmaceuticals, Inc. leads on 9 and Opus Genetics, Inc. on 7.
Valuation
Profitability
| Metric | IRD | SPRY | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 71.37% | 65.16% |
| Operating margin | (513.47%) | (184.96%) | 0.00% |
| Net margin | (1,091.82%) | (184.26%) | 0.00% |
| Free cash flow margin | (412.61%) | (167.97%) | 0.00% |
| Return on equity | (4,796.52%) | (210.37%) | (57.72%) |
| Return on assets | (163.50%) | (76.54%) | (49.22%) |
| Return on invested capital | 0.00% | (335.65%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack